A Comparative Study Between The Levels of Adropin in Iraqi Women with Metabolic Syndrome and Diabetes

Riyam Hussien Assaf; Layla Othman Farhan

doi:10.30526/37.1.3142

Authors

Riyam Hussien Assaf Department of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq.
Layla Othman Farhan Department of Chemistry, College of Sciences for Women, University of Baghdad, Baghdad, Iraq.

DOI:

https://doi.org/10.30526/37.1.3142

Keywords:

Adropin , Body mass index, Cholesterol , diabetes ,Metabolic Syndrome .

Abstract

By measuring Adropin, fasting blood glucose (FBG), cholesterol, high-density lipoprotein (HDL), triglycerides (TG), low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL) in the sera of Iraqi patients with MetS and type 2 diabetes mellitus (T2DM), the current study was designed to compare some crucial markers in metabolic syndrome (MetS) sera and diabetic patients (T2DM) with control. Twenty female subjects were divided into three groups: group I=40 with MetS and group II=40 with T2DM, and 40 healthy subjects were employed as a control group. Compared to the control group, Adropin levels in the Mets group and T2DM group decreased significantly (p < 0.05). In contrast, none of the patient groups (MetS and T2DM) showed any change compared to themselves. In conclusion, according to the present data, higher levels of FBG, lipid profile, and increased blood pressure (BP) were found in patients with MetS and T2DM. A drop in level could be considered a novel indicator of MetS and T2DM. Compared to T2DM patients, Adropin levels are thought to have a more sensitive diagnostic function than those with MetS and newly diagnosed DM.

References

Schneider, J.G.; Tompkins, C.; Blumenthal, R.S.; Mora, S. The metabolic syndrome in women. Cardiol. Rev. 2006, 14(6), 286–291. https://doi: 10.1097/01.crd.0000233757.15181.67. DOI: https://doi.org/10.1097/01.crd.0000233757.15181.67

Kumar, K.G.; Trevaskis, J.L.; Lam, D.D.; Sutton, G.M.; Koza, R.A.; Chouljenko, V.N.; Kousoulas, K.G.; Rogers, P.M.; Kesterson, R.A.; Thearle, M. Identification of Adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008, 8(6), 468–481. https://doi: 10.1016/j.cmet.2008.10.011. DOI: https://doi.org/10.1016/j.cmet.2008.10.011

Gao, S.; McMillan, R.P.; Jacas, J.; Zhu, Q.; Li, X.; Kumar, G.K.; Casals, N.; Hegardt, F.G.; Robbins, P.D.; Lopaschuk, G.D. Regulation of substrate oxidation preferences in muscle by the peptide hormone Adropin. Diabetes 2014, 63(10), 3242–3252. https://doi: 10.2337/db14-0388. DOI: https://doi.org/10.2337/db14-0388

Hamad, H.T; Mohammed, Y.K. Effect of Clopidogrel on the levels of Adropin and Adiponectin in serum of female Albino Rats. International Research Journal of Pharmacy and Medical Sciences (IRJPMS), 2023, 6(6),67-71. http://irjpms.com/wp-content/uploads/2023/10/IRJPMS-V6N6P115Y23.pdf.

Reddy, V.S.; Reddy, E.P.; Thangappazham, B.; Varshney, S.; Das, V.L.; Munikumar, M. Adropin levels and its associations as a fat-burning hormone in patients with polycystic ovary syndrome: A correlational meta-analysis. Gynecol Endocrinol., 2021, 37(10), 879-884. https://doi: 10.1080/09513590.2021.1950136.

Khan, S.;A.; Ram, N.; Masood, M.Q. Patterns of abnormal glucose metabolism in acromegaly and impact of treatment modalities on glucose metabolism. Cureus 2021, 13(3), e13852. https://doi: 10.7759/cureus.13852.

Butler, A.A.; Tam, C.S.; Stanhope, K.L.; Wolfe, B.M.; Ali, M.R.; O’Keeffe, M.; St-Onge, M.-P.; Ravussin, E.; Havel, P.J. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J. Clin. Endocrinol. Metab. 2012, 97(10), 3783–3791. https://doi: 10.1210/jc.2012-2194. DOI: https://doi.org/10.1210/jc.2012-2194

Hamad, M.S.; Sarhat, E.R.; Sarhat, T.R.; ABASS, K.S. Impact of serum Adropin and Irisin in Iraqi patients with congestive heart failure. PJMH S 2021, 15(2), 497–499. https://pjmhsonline.com/2021/feb/497.pdf.

Yu, H.; Zhao, P.; Wu, M.; Liu, J.; Yin, W. Serum Adropin levels are decreased in patients with acute myocardial infarction. Regul. Pept., 2014, 190, 46–49. https://doi: 10.1016/j.regpep.2014.04.001. DOI: https://doi.org/10.1016/j.regpep.2014.04.001

Mustaf, L.A. Adropin levels in the serum of obese type 2 diabetic patients and their relationship to oxidative stress. African J. Adv. Pure Appl. Sci., 2023, 2(2),131–136. https://aaasjournals.com/index.php/ajapas/article/view/343.

Jasaszwili, M.; Billert, M.; Strowski, M.Z.; Nowak, K.W.; Skrzypski, M. Adropin as a fat-burning hormone with multiple functions—Review of a decade of research. Molecules, 2020, 25(3), 549. https://doi.org/10.3390/molecules25030549.

Elgohary, M.; El Maghawry, M.A.; Mostafa, D.; Abd el-Sattar, E.M.; El Tahir, F. The association between serum Adropin level and metabolic complications of type 2 diabetes mellitus. Egypt. J. Hosp. Med., 2023, 93, 7323–7328. https://doi.org/10.1186%2Fs13098-022-00796-y.

Farhan, L.O. Study of partially purification AST activity in sera of Iraqi patients with diabetic nephropathy. Atherosclerosis, 2014, 14(9), 12. https://www.tsijournals.com/articles/study-of-partially-purification-ast-activity-in-sera-of-iraqi-patients-with-diabetic-nephropathy.pdf.

DeMers, D.; Wachs, D. Physiology, mean arterial pressure. StatPearls Publishing, 2021. https://www.ncbi.nlm.nih.gov/books/NBK538226.

Huang, J.-K.; Lee, H.-C. Emerging evidence of pathological roles of very-low-density lipoprotein (VLDL). Int. J. Mol. Sci., 2022, 23(8), 4300. https://doi: 10.3390/ijms23084300.

Bailey, A.; Mohiuddin, S.S. Biochemistry, high density lipoprotein. StatPearls Publishing, 2022. https://www.ncbi.nlm.nih.gov/books/NBK549802.

Haile, K.; Haile, A.; Timerga, A. Predictors of lipid profile abnormalities among patients with metabolic syndrome in Southwest Ethiopia: A cross-sectional study. Vasc. Health Risk Manag., 2021, 17, 461. https://doi.org/10.2147%2FVHRM.S319161.

Abed, B.A.; Al-AAraji, S.B.; Salman, I.N. Estimation of Apelin levels in Iraqi patients with type II diabetic peripheral neuropathy, Baghdad Science Journal, 2023, 20(5), 1684-1691. https://doi.org/10.21123/bsj.2023.7566.

Shi, J.; He, L.; Yu, D.; Ju, L.; Guo, Q.; Piao, W.; Xu, X.; Zhao, L.; Yuan, X.; Cao, Q. Prevalence and correlates of metabolic syndrome and its components in Chinese children and adolescents aged 7–17: The China National Nutrition and Health Survey of Children and Lactating Mothers from 2016–2017. Nutrients 2022, 14(16), 3348. https://doi.org/10.3390%2Fnu14163348.

Khaleel, F.; N-Oda, N.; Abed, B.A. Disturbance of arginase activity and nitric oxide levels in Iraqi type 2 diabetes mellitus. Baghdad Sci. J., 2018, 15(2),189-191. https://doi.org/10.21123/bsj.2018.15.2.0189.

Krishnamoorthy, Y.; Rajaa, S.; Murali, S.; Sahoo, J.; Kar, S.S. Association between anthropometric risk factors and metabolic syndrome among adults in India: A systematic review and meta-analysis of observational studies. Prev. Chronic Dis., 2022, 19, E24. https://doi: 10.5888/pcd19.210231.

Vladu, I.M.; Forțofoiu, M.; Clenciu, D.; Forțofoiu, M.-C.; Pădureanu, R.; Radu, L.; Cojan, Ștefăniță T. Țenea; Rădulescu, P.M.; Pădureanu, V. Insulin Resistance Quantified by the Value of HOMA‑IR and Cardiovascular Risk in Patients with Type 2 Diabetes. Exp. Ther. Med. 2022, 23(1),73. https://doi: 10.3892/etm.2021.10996. E.

Xia, S.-J.; Gao, B.-Z.; Wang, S.-H.; Guttery, D.S.; Li, C.-D.; Zhang, Y.-D. Modeling of diagnosis for metabolic syndrome by integrating symptoms into physiochemical indexes. Biomed. Pharmacother., 2021, 137, 111367. https://doi: 10.1016/j.biopha.2021.111367..

Grigorescu, E.-D.; Lăcătușu, C.-M.; Crețu, I.; Floria, M.; Onofriescu, A.; Ceasovschih, A.; Mihai, B.-M.; Șorodoc, L. Self-reported satisfaction to treatment, quality of life and general health of type 2 diabetes patients with inadequate glycemic control from North-Eastern Romania. Int. J. Environ. Res., Public Health 2021, 18(6),3249. https://doi: 10.3390/ijerph18063249.

Farhan, L.O.; Taha, E.M.; Farhan, A.M. A case control study to determine macrophage migration inhibitor, and N-Telopeptides of type I bone collagen levels in the sera of osteoporosis patients. Baghdad Sci. J., 2022, 19(4), 848-854. https://doi.org/10.21123/bsj.2022.19.4.0848.

Wei, W.; Liu, H.; Qiu, X.; Zhang, J.; Huang, J.; Chen, H.; Qiu, S.; Lin, R.; Li, S.; Tu, M. The association between serum adropin and carotid atherosclerosis in patients with type 2 diabetes mellitus: A cross-sectional study. Diabetol. Metab. Syndr., 2022, 14, 1–8. https://doi.org/10.1186%2Fs13098-022-00796-y.

Zhang, H.; Chen, N. Adropin as an indicator of T2DM and its complications. Food Sci. Hum. Wellness, 2022, 11(6), 1455-1463. https://doi.org/10.1016/j.fshw.2022.06.00228.

Gao, S.; McMillan, R.P.; Zhu, Q.; Lopaschuk, G.D.; Hulver, M.W.; Butler, A.A. Therapeutic effects of Adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Mol. Metab., 2015, 4(4):310-24. https://doi: 10.1016/j.molmet.2015.01.005. DOI: https://doi.org/10.1016/j.molmet.2015.01.005

Ali, I.I.; D’Souza, C.; Singh, J.; Adeghate, E. Adropin’s role in energy homeostasis and metabolic disorders. Int. J. Mol. Sci., 2022, 23(15):8318. https://doi: 10.3390/ijms23158318.

Layla, O.F.; Baydaa, A.A.; Aufaira, S.N.; Wesen, A.M. Total antioxidant capacity and malondialdehyde as a markers of oxidative stress in women with diabetic and disorder hormones. Adv. Environ. Biol., 2016, 10(5), 172-176. https://doi.org/10.1155%2F2013%2F150693.